Advertisement

21st International AIDS Conference (AIDS 2016)

News

Can a Two-Drug Treatment Regimen Keep HIV Under Control?

August 9, 2016

An antiretroviral regimen consisting of just two drugs -- dolutegravir and lamivudine -- led to sustained viral suppression for most people starting HIV treatment for the first time, according to findings from a small study presented in a late-breaker session at the recent 21st International AIDS Conference (AIDS 2016) in Durban, South Africa. Two-drug regimens would potentially be easier to take and less expensive compared to the standard three-drug HIV treatment regimens.

ViiV Healthcare's drug dolutegravir (Tivicay, also in the Triumeq combination pill) is a potent HIV integrase inhibitor with a high barrier to resistance. Lamivudine (3TC or Epivir) is an inexpensive nucleoside reverse transcriptase inhibitor (NRTI) with minimal side effects and no known drug interactions.

Pedro Cahn, M.D., from Fundacion HUESPED in Buenos Aires reported findings from the PADDLE trial, a small proof-of-concept study evaluating dolutegravir plus lamivudine for first-line HIV treatment (abstract FRAB0104LB).

This excerpt was cross-posted with the permission of BETAblog.org. Read the full article.


Related Stories

Dual Therapy With Dolutegravir + 3TC Keep Viral Load Undetectable: 48-Week Results From PADDLE Study
Dolutegravir Is Superior to Boosted Atazanavir in Women in the ARIA Study



Visit their website at www.betablog.org.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.